MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

Rhea-AI Summary

MBX Biosciences (Nasdaq: MBX) has announced it will release topline results from its Phase 2 clinical trial of canvuparatide, a potential once-weekly treatment for chronic hypoparathyroidism (HP). The company will host an investor webcast and conference call on Monday, September 22 at 8 AM ET to discuss the Avail™ Phase 2 trial results.

Investors can access the presentation through a live webcast or by dialing 1-877-407-0779 (US) or 1-201-389-0914 (international). The webcast and slide presentation will be available on the company's investor relations website.

News Market Reaction

-0.70% 4.2x vol

14 alerts

-0.70% News Effect

+29.9% Peak in 2 hr 21 min

-$2M Valuation Impact

$336M Market Cap

4.2x Rel. Volume

On the day this news was published, MBX declined 0.70%, reflecting a mild negative market reaction. Argus tracked a peak move of +29.9% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $336M at that time. Trading volume was very high at 4.2x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) and host an investor webcast on Monday, September 22.

The Company will host a conference call and webcast at 8 am ET on Monday, September 22 to discuss the results from the Avail™ Phase 2 trial. Those who would like to participate may access the live webcast here or dial 1-877-407-0779 (US) or 1-201-389-0914 (international). The live and archived webcast of the call and slide presentation will be available in the Investors section of the Company’s website at https://investors.mbxbio.com/news-events/events.

About MBX Biosciences 
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.

Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
IECommsMBX@inizioevoke.com
(937) 232-4889

Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com

FAQ

When will MBX Biosciences announce the Phase 2 trial results for canvuparatide?

MBX Biosciences will announce the Phase 2 trial results on Monday, September 22, 2025, at 8:00 AM ET via a conference call and webcast.

What is the purpose of MBX Biosciences' canvuparatide clinical trial?

The clinical trial is evaluating canvuparatide as a potential once-weekly treatment for patients with chronic hypoparathyroidism (HP).

How can investors access MBX Biosciences' Phase 2 trial results presentation?

Investors can access the presentation through a live webcast or by calling 1-877-407-0779 (US) or 1-201-389-0914 (international). The webcast will also be available on the company's investor website.

What type of company is MBX Biosciences (Nasdaq: MBX)?

MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing novel precision peptide therapies for endocrine and metabolic disorders.